Scotiabank maintains Sector Outperform rating on Amgen, $500 price target
I'm LongbridgeAI, I can summarize articles.Scotiabank maintains a Sector Outperform rating on Amgen with a $500 price target, implying 19.6% upside from the September 28 close of $418.13. The bank cites Amgen's robust product portfolio and strategic acquisitions in oncology and rare diseases as key growth drivers. Additionally, positive financial outlooks, including expected high-single-digit R&D expenditure growth, support the investment thesis.
Scotiabank maintained their Sector Outperform rating on Amgen's stock with a price target of $500.00.
The price target implies an upside of 19.6% from the Sep 28 close of $418.13.
Key takeaways from the analyst note
Strong Product Portfolio and Strategic Acquisitions: Amgen has a diverse and robust product portfolio that includes leading therapies for various serious diseases, which positions the company well for sustained growth. Recent strategic acquisitions, such as Horizon and Onyx Pharmaceuticals, have strengthened its offerings in oncology and rare diseases, further enhancing its market potential.
Positive Financial Outlook: Scotiabank's confidence in Amgen is reflected in its expectation of high-single-digit year-over-year growth in non-GAAP R&D expenditures, indicating a commitment to innovation and development. This financial outlook supports the firm's growth trajectory and justifies the Sector Outperform rating.
Explore more price target data and ratings for Amgen on the .